GLP-3 – Next-Generation Incretins

Experimental Triple Agonists | For Research Use Only

What is "GLP-3"?
"GLP-3" is an informal term used to describe a new class of experimental triple-agonist peptides that act on three metabolic receptors: GLP-1, GIP, and glucagon.
It is not a single compound, but a scientific concept. A well-known example under clinical investigation is Ret4trutid3.

How does it work?

• GLP-1 & GIP: reduce appetite and improve insulin sensitivity

• Glucagon: increases energy expenditure and promotes fat burning

By targeting all three pathways, triple agonists aim to deliver broader metabolic effects than single or dual agonists.

Key effects under investigation:

• Strong appetite suppression

• Greater weight loss compared to dual agonists (e.g. Tirz3p4tide)

• Increased basal metabolic rate

• Potential reduction of liver fat

• Improved overall metabolic health

Research status:
Triple agonists are strictly in the research phase. Early clinical trials with Ret4trutid3 have reported average weight reductions of over 20% within one year, considered highly significant in metabolic research.

Important notice:
⚠️ For research purposes only.
Not approved for human use. Long-term safety has not been established. Any non-clinical use is strongly discouraged.